Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Shareholders of Nizhnekamskneftekhim approved dividends for 2023

7/2/24 NKNC

Shareholders of Lenzoloto approved dividends for 2023

7/2/24 LNZL

Gazprom Neft estimated the share of hard-to-recover reserves in production

7/2/24 SIBN

Segezha plans to export to Asia 60 thousand cubic meters of products

7/2/24 SGZH

Seligdar discovered the Ryabchik deposit

7/2/24 SELG

Shareholders of Abrau-Durso approved dividends for 2023

7/2/24 ABRD

Shareholders of Ufaorgsintez approved dividends for 2023

7/2/24 UFOSP

Finland may ban cab service Yango

7/2/24 YDEX

Revenue of Mosgorlombard in the first half of the year increased 4.6 times

7/2/24 MGKL

MTS Live will launch its own clown theater

7/2/24 MTSS